Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4618904 | 0.82 | ALDH1A1 (0.68) | ALDH1A1MAPK1USP2PKMTSHR | |
| SCHEMBL3719058 | 0.81 | PKM (0.69) | ALDH1A1MAPK1PKMKMT2AMEN1 | |
| SCHEMBL4618073 | 0.81 | ALDH1A1 (0.62) | ALDH1A1MAPK1PKMKMT2AMEN1 | |
| SCHEMBL4616479 | 0.79 | SFRP1 (0.74) | ALDH1A1MAPK1USP2PKMTSHR | |
| SCHEMBL6103833 | 0.78 | KMT2A (0.59) | ALDH1A1MAPK1PKMKMT2ASMN1; SMN2 | |
| SCHEMBL4616589 | 0.78 | SMN1; SMN2 (0.69) | ALDH1A1MAPK1PKMTSHRKMT2A | |
| SCHEMBL4638749 | 0.76 | SFRP1 (0.66) | ALDH1A1MAPK1TSHRKMT2ASMN1; SMN2 | |
| SCHEMBL4618946 | 0.75 | SFRP1 (0.64) | ALDH1A1SMN1; SMN2L3MBTL1HSD17B10 | |
| SCHEMBL4618346 | 0.75 | SFRP1 (0.61) | ALDH1A1MAPK1PKM | |
| SCHEMBL4616745 | 0.74 | POLB (0.69) | ALDH1A1KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060276464-A1 | Diarylsulfone sulfonamides and use thereof | WYETH (US) | 2006-12-07 | — | — | US | claimed |
| EP-1879859-A2 | DIARYLSULFONE SULFONAMIDES AND USE THEROF | Wyeth a Corporation of the State of Delaware (US) | 2008-01-23 | — | — | EP | disclosed |
| US-20060276464-A1 | Diarylsulfone sulfonamides and use thereof | WYETH (US) | 2006-12-07 | — | — | US | disclosed |
| WO-2006124875-A2 | DIARYLSULFONE SULFONAMIDES AND USE THEROF | WYETH (US) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276464-A1 | Diarylsulfone sulfonamides and use thereof | SFRP1, SOS1, FZD7 | ALDH1A1 1865/4885MAPK1 934/4885USP2 2796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.